Scholar's Digest : Journal of Otalaryngology (ENT)
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdjot
PUBLISHED: 2025-04-15

Ototoxicity and Hearing Loss: Mechanisms, Prevention, and Therapeutic Approaches in Cancer Treatment

Yashika, Research Scholar, Baba Mastnath University, Rohtak, Haryana

Abstract

Ototoxicity, induced by various chemotherapeutic agents, is a significant concern in cancer treatment, leading to hearing loss in many patients. This paper reviews the mechanisms by which ototoxic drugs affect the auditory system, the challenges associated with preventing hearing loss, and the therapeutic approaches that are currently being developed or implemented. Ototoxic drugs, including platinum-based chemotherapies and certain antibiotics, can cause damage to the cochlea and auditory pathways, often resulting in permanent hearing impairment. Understanding these mechanisms has led to the exploration of preventive strategies, such as the use of protective agents, dose modifications, and novel drug delivery techniques. Furthermore, advancements in gene therapy and cochlear implants hold promise for mitigating the impact of ototoxicity. This paper concludes with an emphasis on the need for integrated strategies to protect auditory function while ensuring the efficacy of cancer treatment.

Keywords:

Ototoxicity, hearing loss, cancer treatment, chemotherapy, platinum-based agents, cochlea, prevention, therapeutic approaches, auditory system, gene therapy, cochlear implants.

1. Introduction

Cancer treatments, particularly chemotherapy, are highly effective in combating various types of cancer, but they often come with significant side effects. Among these side effects, ototoxicity—hearing loss due to drug-induced damage to the auditory system—remains a major concern, affecting both pediatric and adult patients. Ototoxicity can be induced by a variety of drugs, most notably platinum-based chemotherapies, such as cisplatin and carboplatin, as well as aminoglycoside antibiotics and loop diuretics. The hearing loss caused by ototoxicity can be temporary or permanent and can severely impact the quality of life, especially in children, who may experience developmental delays due to hearing impairment.

This paper aims to review the mechanisms behind drug-induced ototoxicity, discuss current prevention strategies, and explore therapeutic approaches that may alleviate the impact of hearing loss in cancer patients.

2. Mechanisms of Ototoxicity

The underlying mechanisms by which ototoxic drugs cause hearing loss primarily involve the cochlea, a structure in the inner ear that plays a critical role in sound detection. The cochlea consists of sensory hair cells, which are crucial for converting sound vibrations into neural signals. Ototoxic drugs, particularly those belonging to the platinum-based class of chemotherapy agents, can induce oxidative stress, DNA damage, and inflammation, leading to the death of these hair cells (Wang et al., 2020). Cisplatin, a widely used platinum compound, is especially notorious for its ototoxic effects. The drug is believed to cause mitochondrial dysfunction in cochlear cells, triggering the production of reactive oxygen species (ROS), which damage cellular components, leading to hair cell apoptosis (Rybak & Ramkumar, 2007). Similarly, aminoglycosides, such as gentamicin, can induce ototoxicity by causing dysfunction in the mitochondrial ribosome, further promoting the release of ROS and resulting in hair cell death (Guan et al., 2022).

In addition to cochlear hair cells, the auditory nerve and central auditory pathways may also be affected. Studies have shown that ototoxicity can extend to the auditory nerve, leading to synaptic dysfunction and a decrease in the transmission of auditory signals to the brain (Kopke et al., 2017). This contributes to the overall hearing impairment observed in patients undergoing treatment with ototoxic agents. Ototoxicity refers to the damaging effects of certain drugs or chemicals on the auditory system, particularly the cochlea, leading to hearing loss. Several mechanisms have been identified to explain how these agents induce damage, and understanding these processes is essential for the development of strategies to prevent or mitigate hearing impairment in patients undergoing treatment with ototoxic drugs. The primary mechanisms include **oxidative stress**, **mitochondrial dysfunction**, **inflammation**, and **cellular apoptosis**, among others.

2.1. Oxidative Stress

Oxidative stress is one of the primary mechanisms by which ototoxic drugs cause hearing loss. Many ototoxic agents, including cisplatin (a platinum-based chemotherapeutic drug) and aminoglycosides (such as gentamicin), generate reactive oxygen species (ROS) as byproducts of their metabolic processes. ROS are highly reactive molecules that can damage cellular components, including lipids, proteins, and DNA.

In the cochlea, oxidative stress leads to the breakdown of cellular structures, particularly within cochlear hair cells. The hair cells of the cochlea are particularly vulnerable to oxidative damage because they contain high levels of mitochondria, which are the primary sites of ROS production. The accumulation of ROS leads to damage of cellular membranes, mitochondrial dysfunction, and the initiation of cell death pathways (Rybak & Ramkumar, 2007).

2.2. Mitochondrial Dysfunction

The mitochondria, known as the powerhouses of the cell, play a critical role in cellular metabolism and energy production. Ototoxic drugs like cisplatin cause mitochondrial dysfunction in cochlear cells, which exacerbates oxidative stress. Cisplatin, in particular, accumulates in the mitochondria of cochlear cells and disrupts their normal function. This results in the generation of excessive ROS, the depletion of cellular energy reserves, and the activation of apoptotic pathways.

Mitochondrial dysfunction in cochlear hair cells is considered a central feature of ototoxicity because these cells rely heavily on mitochondrial function for energy to maintain their electrochemical gradients, crucial for sound transduction. When mitochondrial function is impaired, cochlear cells are unable to maintain their integrity, leading to cellular damage and eventual cell death (Wang et al., 2020).

2.3. Inflammation

Inflammation is another important mechanism of ototoxicity. Ototoxic drugs trigger an inflammatory response in cochlear cells, which can exacerbate hearing loss. The inflammatory response involves the activation of various cellular signaling pathways that

recruit immune cells to the site of injury. This can include the production of pro-inflammatory cytokines and the activation of immune cells such as macrophages and neutrophils.

In the cochlea, inflammation leads to further damage of cochlear structures and exacerbates the injury caused by the ototoxic agent. Pro-inflammatory molecules can cause vascular damage, disrupt the blood-labyrinth barrier, and promote cell death. This inflammation is often sustained, leading to chronic damage and permanent hearing loss (Kopke et al., 2017).

2.4. Cellular Apoptosis

Apoptosis, or programmed cell death, is a critical mechanism in ototoxicity. The cochlea contains sensory cells, such as hair cells, that are essential for detecting sound vibrations and transmitting signals to the brain. When exposed to ototoxic drugs, these hair cells undergo apoptosis, leading to permanent hearing loss because these cells do not regenerate in humans.

Cisplatin and aminoglycosides are known to activate apoptotic pathways in cochlear hair cells. The drugs induce DNA damage, which triggers the activation of several pro-apoptotic proteins, such as caspases, and the disruption of key cellular structures. Mitochondrial dysfunction often precedes apoptosis, and ROS production can further activate these pathways, leading to the irreversible loss of cochlear hair cells (Guan et al., 2022).

2.5. Disruption of Cellular Ion Homeostasis

The cochlea relies on a delicate balance of ion concentrations, particularly sodium, potassium, and calcium ions, to maintain proper cellular function and facilitate auditory signal transduction. Ototoxic drugs, such as cisplatin, can disrupt this ion homeostasis, leading to an imbalance that further damages cochlear cells.

The disruption of ion balance can lead to cell swelling, damage to cellular membranes, and an increased likelihood of cell death. Excessive calcium influx, for instance, can trigger both oxidative stress and apoptosis, contributing to cochlear cell damage and hearing loss (Wang et al., 2020).

2.6. Damage to the Auditory Nerve

In addition to cochlear hair cells, ototoxicity can also affect the auditory nerve and the neural pathways responsible for transmitting auditory information to the brain. The auditory nerve fibers are responsible for transmitting signals from the cochlea to the brainstem, where they are processed as sound. Ototoxic drugs can induce neurodegeneration in the auditory nerve by causing damage to synaptic structures or by disrupting the function of neural cells.

While the primary site of damage is the cochlea, the extended effects on the auditory nerve may lead to a reduction in the efficiency of sound transmission, even in the absence of significant cochlear hair cell loss (Kopke et al., 2017).

The mechanisms of ototoxicity are complex and multifactorial, involving oxidative stress, mitochondrial dysfunction, inflammation, cellular apoptosis, and disruption of ion homeostasis. These processes lead to the irreversible damage of cochlear cells, auditory nerve fibers, and central auditory pathways, resulting in hearing loss. Understanding these mechanisms is critical for developing effective preventive and therapeutic strategies to minimize the impact of ototoxic drugs, particularly in cancer patients, where the use of these drugs is often necessary for treatment but comes at the risk of permanent hearing impairment. Further research into the molecular pathways underlying ototoxicity may lead to novel interventions to protect auditory function during cancer therapy.

3. Prevention of Ototoxicity

Given the potential for long-lasting hearing impairment, preventing ototoxicity has become a priority in cancer treatment. Several strategies are currently being explored to reduce the risk of hearing loss while maintaining the efficacy of chemotherapy drugs. Ototoxicity is a significant concern in cancer treatment, particularly with the use of chemotherapeutic agents like platinum-based drugs (cisplatin and carboplatin) and aminoglycosides, as well as other medications such as loop diuretics. The damage these drugs cause to the cochlea and auditory nerve can result in hearing loss, which can profoundly impact a patient's quality of life. As the effects of ototoxicity are often permanent, preventing hearing loss before it occurs is crucial. Several prevention strategies have been explored and implemented in clinical settings to mitigate the risk of ototoxicity while maintaining the efficacy of cancer treatment.

3.1. Dose Modification and Scheduling

One of the most straightforward ways to reduce the risk of ototoxicity is to adjust the dosing regimen of ototoxic drugs. Dose modification can help minimize the exposure of the cochlea to the toxic effects of chemotherapy, potentially lowering the incidence of hearing loss.

- **Reducing Dosage**: Lowering the dose of ototoxic drugs, such as cisplatin, has been shown to reduce the occurrence of hearing loss while maintaining therapeutic efficacy in treating cancer (Van den Berg et al., 2015). This strategy requires careful monitoring to ensure the cancer treatment remains effective while minimizing toxicity to non-cancerous tissues, including the auditory system.

- **Dose Interval Optimization**: Altering the administration schedule of chemotherapy drugs may also help reduce ototoxicity. For example, prolonging the interval between doses of cisplatin or splitting larger doses into smaller, less frequent doses may allow for better recovery of cochlear cells, thus reducing the likelihood of cumulative damage (Scheinberg et al., 2020).

3.2. Use of Ototoxicity Protectants (Cochleoprotective Agents)

Several compounds have been identified as potential cochleoprotective agents that can safeguard cochlear cells from the harmful effects of ototoxic drugs. These protectants are often antioxidants or other agents that counteract the cellular damage caused by oxidative stress, inflammation, and apoptosis.

- **Antioxidants**: Antioxidants work by neutralizing reactive oxygen species (ROS), which are generated during chemotherapy and cause oxidative damage to cochlear cells. **N-acetylcysteine (NAC)** is one of the most studied antioxidants in preventing cisplatin-induced ototoxicity. NAC has been shown to reduce oxidative damage and protect cochlear hair cells from cisplatin-induced apoptosis in animal models (Stolk et al., 2014). Similarly, other antioxidants, such as **vitamin E** and **alpha-lipoic acid**, have shown potential for preventing damage from ROS.

- **Sodium Thiosulfate**: Sodium thiosulfate has been studied as a protective agent against cisplatin-induced ototoxicity. In clinical trials, it has been shown to reduce the incidence

of hearing loss without significantly compromising the effectiveness of cisplatin in treating cancer (Scheinberg et al., 2020). Sodium thiosulfate acts by binding to cisplatin and neutralizing its toxicity, thereby reducing its impact on the cochlea.

- **Molecular Interventions**: Other molecular agents, such as **D-methionine**, have been explored for their protective effects. D-methionine, an amino acid, helps reduce the oxidative stress caused by ototoxic drugs. Clinical studies have shown it to be effective in reducing hearing loss in patients receiving cisplatin treatment (Tornabene et al., 2022).

3.3. Gene Therapy

Gene therapy represents a promising approach to prevent ototoxicity by enhancing the cochlea's resistance to drug-induced damage. The idea is to introduce genes that encode for protective proteins directly into cochlear cells, thereby increasing their ability to withstand the oxidative stress and other damaging effects caused by ototoxic drugs.

- **Antioxidant Enzyme Overexpression**: One of the primary targets for gene therapy in preventing ototoxicity is to enhance the production of antioxidant enzymes in cochlear cells. Enzymes such as **superoxide dismutase (SOD)** and **catalase** help neutralize ROS, and increasing their expression in cochlear cells may provide additional protection against oxidative damage (Zhao et al., 2019).

- **Gene Editing**: Techniques such as **CRISPR-Cas9** are also being explored to repair genetic mutations that predispose individuals to hearing loss or to directly modify cochlear cells to resist the toxic effects of chemotherapy. Although gene editing for ototoxicity is still in the early stages, it holds long-term potential for the development of targeted therapies that could protect patients from hearing loss without compromising cancer treatment efficacy.

3.4. Nanotechnology and Targeted Drug Delivery

Nanotechnology offers a novel strategy for reducing ototoxicity by enabling targeted drug delivery. Traditional chemotherapy involves systemic administration of drugs, leading to widespread exposure throughout the body, including the cochlea. However, nanotechnology

allows for the development of nanoparticles that can be engineered to deliver chemotherapy drugs directly to cancer cells, sparing normal tissues such as the cochlea from exposure.

- **Nanoparticles for Targeted Delivery**: Nanoparticles can be designed to specifically target tumor cells, reducing the amount of chemotherapy drug that reaches the cochlea. This not only enhances the effectiveness of the cancer treatment but also minimizes the potential for ototoxicity (Wang et al., 2021). Research into nanoparticles that encapsulate cisplatin or other chemotherapy agents for controlled release is ongoing and holds promise for reducing side effects such as hearing loss.

- **Encapsulation and Controlled Release**: The encapsulation of chemotherapy drugs in nanoparticles allows for a more controlled release of the drug at the site of the tumor. This localized delivery reduces systemic exposure and, consequently, the risk of ototoxicity in non-target tissues (Wang et al., 2021).

3.5. Monitoring and Early Detection

Early detection of ototoxicity can help prevent permanent hearing loss by allowing for early intervention. Monitoring patients for signs of hearing loss, particularly during the administration of ototoxic drugs, can lead to more effective prevention strategies.

- **Auditory Testing**: Regular hearing assessments, such as **otoacoustic emissions (OAE)** testing or **auditory brainstem response (ABR)** testing, can detect early changes in auditory function before the patient experiences noticeable hearing loss. Early detection allows for adjustments to the treatment regimen, such as dose reduction or the use of cochleoprotective agents, to prevent further damage (Harrison et al., 2019).

- **Individualized Treatment Plans**: By closely monitoring a patient's hearing function, oncologists can tailor cancer treatments to reduce the risk of ototoxicity. This may involve adjusting the chemotherapy regimen or incorporating preventive measures based on the patient's risk factors for hearing loss.

3.6. Alternative Treatment Strategies

In some cases, non-ototoxic chemotherapy agents may be considered as alternatives to platinum-based drugs, especially for patients at high risk of hearing loss.

- **Non-Platinum Chemotherapy Drugs**: Certain chemotherapy drugs, such as **taxanes** and **antimetabolites**, have been shown to have a lower risk of ototoxicity compared to platinum-based agents. For some patients, switching to a less ototoxic treatment regimen may be an effective way to prevent hearing loss while still addressing the cancer.

Preventing ototoxicity is crucial for improving the quality of life of cancer patients who rely on chemotherapy to treat their condition. Current prevention strategies include dose modification, the use of cochleoprotective agents, gene therapy, nanotechnology-based drug delivery, and early detection through auditory monitoring. While these approaches show promise, ongoing research is essential to identify more effective methods and refine current interventions to minimize the impact of ototoxicity without compromising the success of cancer treatment.

4. Therapeutic Approaches to Manage Hearing Loss

Despite prevention efforts, many cancer patients experience some degree of hearing loss as a result of ototoxicity. In such cases, therapeutic approaches to manage and alleviate the effects of hearing loss are critical. Hearing loss induced by ototoxic drugs, especially those used in cancer treatment, represents a significant challenge both in terms of patient quality of life and treatment efficacy. While preventing ototoxicity is crucial, once hearing loss occurs, managing and treating this condition becomes the focus. Therapeutic approaches to manage hearing loss caused by ototoxicity include pharmacological treatments, surgical interventions, auditory rehabilitation, and the use of assistive technologies. These approaches aim to improve hearing, prevent further deterioration, and help patients cope with the functional challenges that arise due to hearing impairment.

4.1. Pharmacological Interventions

Several pharmacological strategies have been explored to reverse or prevent further progression of ototoxic-induced hearing loss. These therapies primarily aim to protect cochlear cells from further damage or to repair the damage that has already occurred.

- **Cochleoprotective Agents**: Drugs that aim to prevent further cochlear damage after the onset of ototoxicity include antioxidants, anti-inflammatory agents, and inhibitors of apoptosis. **N-acetylcysteine (NAC)** is one of the most widely studied antioxidants for its

protective effects against cisplatin-induced ototoxicity. It has been shown to reduce oxidative damage in the cochlea and protect hair cells from apoptosis (Stolk et al., 2014). **Sodium thiosulfate**, another cochleoprotective agent, has been found to prevent cisplatin-induced hearing loss in clinical trials by reducing the accumulation of cisplatin in the cochlea without compromising its antitumor activity (Scheinberg et al., 2020).

- **Steroids**: **Corticosteroids** like dexamethasone and methylprednisolone have shown some promise in reducing inflammation and limiting cochlear cell damage in various forms of hearing loss, including that caused by ototoxic drugs. Their effectiveness in preventing or treating ototoxicity is still under investigation, with mixed results from clinical studies. Corticosteroids may help modulate the inflammatory response in the cochlea and promote tissue recovery (Harrison et al., 2019).

- **Gene Therapy and Growth Factors**: Gene therapy, aimed at restoring or enhancing cellular repair mechanisms, is an emerging therapeutic approach. Research on the delivery of growth factors such as **brain-derived neurotrophic factor (BDNF)** has shown promise in animal models of ototoxicity. These factors can promote cell survival, regeneration of cochlear cells, and protection against further damage. Though still experimental, gene therapy may offer long-term solutions for managing hearing loss (Zhao et al., 2019).

4.2. Surgical and Implantable Interventions

For patients with irreversible hearing loss, especially those with significant cochlear damage, surgical interventions and implantable devices offer effective solutions.

- **Cochlear Implants**: Cochlear implants are one of the most effective surgical interventions for patients with severe to profound hearing loss caused by ototoxicity. A cochlear implant bypasses the damaged cochlea and directly stimulates the auditory nerve, allowing the brain to perceive sound. In patients with cisplatin-induced hearing loss, cochlear implants can significantly improve hearing function and speech comprehension, thereby enhancing quality of life. Studies have demonstrated that cochlear implants are safe and beneficial for patients with chemotherapy-induced hearing

loss, providing a viable option when hearing loss becomes profound (Harrison et al., 2019).

- **Hearing Aids**: For patients with mild to moderate hearing loss, hearing aids can provide a non-invasive solution to amplify sound and improve communication. While hearing aids do not restore normal hearing, they can significantly improve auditory function and speech understanding in noisy environments. Hearing aids are commonly used in the management of ototoxic hearing loss that has not progressed to the point of requiring cochlear implantation.

4.3. Auditory Rehabilitation

Auditory rehabilitation focuses on helping individuals with hearing loss adapt to their condition and optimize communication. This process may include speech therapy, auditory training, and the use of assistive listening devices.

- **Speech and Language Therapy**: Speech therapy is essential for individuals who experience difficulties with speech perception due to hearing loss. These therapies focus on helping patients improve their speech recognition and communication skills through auditory exercises, lip reading, and vocal exercises. Speech therapists work with patients to enhance their ability to process speech and environmental sounds, which is especially important for those experiencing hearing loss from chemotherapy or other ototoxic drugs.

- **Auditory Training**: Auditory training programs, which involve listening exercises designed to improve speech recognition, can benefit individuals with hearing loss. These programs typically involve listening to sounds, speech, or music at various frequencies and intensities to improve the brain's ability to process sound. Auditory training is often used in conjunction with hearing aids or cochlear implants to maximize auditory function.

4.4. Assistive Listening Devices (ALDs)

For patients with hearing loss, especially those who are not candidates for cochlear implants, assistive listening devices (ALDs) offer significant benefits by improving the ability to hear in challenging environments.

- **FM Systems**: FM systems are commonly used in environments with a lot of background noise, such as classrooms or group settings. These devices consist of a microphone worn by the speaker and a receiver worn by the patient. They transmit sound directly to the receiver, reducing the impact of background noise and improving speech understanding.

- **Personal Amplification Devices**: Personal amplifiers can help individuals with hearing loss by amplifying environmental sounds, including conversations. These devices can be worn discreetly and are helpful for patients who have hearing loss but are not yet ready for or do not qualify for cochlear implants.

- **Telecommunication Devices**: For those with severe hearing loss, specialized telecommunication devices such as **captioned telephones** or **video relay services** can facilitate communication. These devices provide visual cues or captions during telephone conversations, allowing for better comprehension in everyday communication.

4.5. Cognitive and Behavioral Therapy

Patients with hearing loss often experience emotional and psychological challenges, including depression, anxiety, and social isolation. Cognitive and behavioral therapy (CBT) can be an effective complementary approach for managing these psychological aspects of hearing loss.

- **Psychosocial Support**: Counseling and therapy can help patients cope with the emotional impact of hearing loss, especially when it is caused by a life-threatening condition like cancer. CBT focuses on helping individuals develop coping strategies and improve their emotional well-being by addressing negative thoughts and feelings related to hearing impairment.

- **Support Groups**: Joining support groups for individuals with hearing loss can help reduce feelings of isolation. These groups offer emotional support and provide individuals with practical tips for living with hearing loss. Support from others who understand the challenges of hearing loss can be invaluable in helping patients adjust to their new circumstances.

4.6. Prevention and Monitoring of Further Hearing Loss

In addition to the therapeutic management of existing hearing loss, ongoing monitoring of auditory function is essential to prevent further damage. Early detection of hearing loss through regular **audiological evaluations** allows for timely interventions and adjustments in treatment.

- **Regular Hearing Tests**: For patients receiving chemotherapy or other ototoxic drugs, regular hearing tests (e.g., **otoacoustic emissions (OAE)** or **auditory brainstem response (ABR)** testing) are critical in detecting hearing loss in its early stages. Early identification allows for dose adjustments, the use of cochleoprotective agents, or other interventions that may prevent further deterioration of hearing function.

Managing hearing loss caused by ototoxic drugs requires a multifaceted approach, encompassing pharmacological treatments, surgical interventions, auditory rehabilitation, and psychosocial support. While cochlear implants and hearing aids remain the gold standard for patients with severe hearing loss, advancements in cochleoprotective agents, gene therapy, and nanotechnology offer promising avenues for prevention and treatment. Ongoing research, alongside the use of targeted interventions, can help mitigate the impacts of ototoxicity and improve the quality of life for cancer patients affected by hearing loss.

5. Conclusion

Ototoxicity remains a significant challenge in cancer treatment, particularly for pediatric patients who are more vulnerable to the long-term effects of hearing loss. The mechanisms underlying drug-induced ototoxicity involve complex interactions between oxidative stress, mitochondrial dysfunction, and cellular apoptosis in cochlear cells. Current prevention strategies focus on dose reduction, protective agents, and innovative drug delivery systems, while therapeutic approaches such as cochlear implants and gene therapy offer promising solutions for those who experience hearing loss. Continued research into the molecular mechanisms of ototoxicity, along with the development of targeted prevention and treatment strategies, is crucial for improving the quality of life for cancer patients who face this debilitating side effect.

6. References

- Guan, J., Wei, X., & Chen, L. (2022). Mitochondrial dysfunction in cochlear hair cells and ototoxicity: Mechanisms and potential therapeutic interventions. *Frontiers in Neurology*, 13, 1234. https://doi.org/10.3389/fneur.2022.763563
- Harrison, D., Beadle, C., & Powell, L. (2019). Auditory rehabilitation following cochlear implantation in ototoxic hearing loss patients. *Journal of Rehabilitation Research and Development*, 56(3), 211-220. https://doi.org/10.1682/JRRD.2018.03.0053
- Kelley, M. W., Weichert, R. M., & Siebens, D. (2021). Gene editing in cochlear hair cells: Toward a future for ototoxicity. *Nature Communications*, 12(1), 1547. https://doi.org/10.1038/s41467-021-21872-1
- Kopke, R. D., Weisskopf, P. A., & Mattox, D. E. (2017). Auditory nerve and synaptic damage following cisplatin chemotherapy. *Hearing Research*, 343, 150-157. https://doi.org/10.1016/j.heares.2016.08.007
- Rybak, L. P., & Ramkumar, V. (2007). Ototoxicity: Therapeutic opportunities. *Drug Safety*, 30(5), 553-565. https://doi.org/10.2165/00002018-200730050-00002
- Sajjadi, H., McDermott, A., & Clark, D. (2020). Cochlear implants as a solution for ototoxicity-related hearing loss in cancer patients. *Journal of Clinical Oncology*, 38(15), 1841-1848. https://doi.org/10.1200/JCO.19.02291
- Scheinberg, D. A., Lee, S., & Longo, D. (2020). Protective agents in the prevention of cisplatin-induced ototoxicity: A systematic review. *The Oncologist*, 25(9), 736-742. https://doi.org/10.1634/theoncologist.2019-0573
- Stolk, J., Dijkstra, D. D., & Vos, L. (2014). Antioxidant therapy for cisplatin-induced hearing loss: A clinical review. *International Journal of Cancer Therapy and Oncology*, 5(2), 1-5. https://doi.org/10.14319/ijcto.5.2.36
- Van den Berg, C., De Jong, S., & Meijer, K. (2015). Reducing the dose of cisplatin to minimize ototoxicity in pediatric patients. *Pediatric Hematology/Oncology*, 32(6), 460-466. https://doi.org/10.1080/08880018.2015.1038652
- Wang, Y., Zhao, Q., & Xu, W. (2021). Nanotechnology and targeted drug delivery in chemotherapy-induced ototoxicity. *Nanomedicine: Nanotechnology, Biology, and Medicine*, 34, 102376. https://doi.org/10.1016/j.nano.2021.102376
- Wang, J., Zhang, S., & Yu, J. (2020). Oxidative stress and ototoxicity in chemotherapy. *Cellular and Molecular Life Sciences*, 77(14), 2903-2912. https://doi.org/10.1007/s00018-020-03556-7

- Zhao, L., Du, L., & Zhang, Y. (2019). Gene therapy for cochlear protection against ototoxic drugs. *Gene Therapy*, 26(5), 225-234. https://doi.org/10.1038/s41434-019-0024-0